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Recurrent skin infections in extrinsic atopic dermatitis (EAD) may be because of the suppression of anti-microbial
peptide (AMP) expression by interleukin (IL)-4 and IL-13. Twenty to thirty percent of AD, however, are classiﬁed as
intrinsic atopic dermatitis (IAD). They exhibit normal serum IgE levels, no allergen-specific sensitization, and lower
levels of IL-4 and IL-13 than EAD. Both forms of AD have increased propensity to skin infection, suggesting a novel
mechanism for infection in IAD. In this study, we observed significantly decreased human b-defensin (HBD)-2 gene
expression in the skin of both IAD (p¼ 0.010) and EAD (p¼ 0.004), as compared with psoriasis patients. Conversely,
IAD (p¼ 0.019) and EAD (p¼ 0.002) skin lesions exhibited elevated IL-10 gene expression when compared with
psoriasis. Using primary keratinocytes, we found that the deﬁciency in AMP expression is an acquired rather than a
constitutive defect. Interestingly, neutralizing antibodies to IL-10 augmented the production of tumor necrosis
factor-a and interferon-c by peripheral blood mononuclear cell from AD patients. Additionally, treatment of AD skin
explants with anti-IL-10 augmented the expression of both HBD-2 and LL-37. Thus, increased levels of IL-10 may
contribute to the AMP deﬁciency in both IAD and EAD by reducing cytokines that induce AMP.
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Atopic dermatitis (AD) is a chronic inflammatory skin disor-
der that is associated with skin infection or colonization with
Staphylococcus aureus in 490% of patients (Leung and
Bieber, 2003; Leung et al, 2004). Two subsets of AD have
been described: 70%–80% have elevated serum IgE and
allergic sensitization, whereas 20%–30% of patients exhibit
normal serum IgE levels and lack allergen-specific sen-
sitization (Novak and Bieber, 2003). These latter patients are
classified as having non-atopic eczema, non-IgE mediated,
or intrinsic AD (IAD). Patients are diagnosed as IAD by the
following criteria: (1) the clinical appearance of AD accord-
ing to the criteria outlined by Hanifin and Rajka (1980), (2)
low serum IgE levels, and (3) lack of allergen-specific sen-
sitization (Oppel et al, 2000; Johansson et al, 2004).
Recent studies have demonstrated that the Th2 cyto-
kines, interleukin (IL)-4 and IL-13, downregulate anti-micro-
bial peptide (AMP) expression in atopic eczema or extrinsic
AD (EAD) skin, and this may account for their propensity
toward recurrent skin infections (Ong et al, 2002; Nomura
et al, 2003). But patients with IAD, as compared with EAD,
express significantly lower levels of IL-4 and IL-13 in their
skin and peripheral blood (Kagi et al, 1994; Akdis et al, 1999;
Jeong et al, 2003). This explains the normal levels of serum
IgE found in IAD as compared with EAD. It does not explain,
however, why both groups of AD suffer from recurrent skin
infections, and suggests that a mechanism other than in-
creased expression of IL-4 and IL-13 may account for in-
creased skin infection in IAD.
Two major classes of AMP—b-defensins (Harder et al,
1997) and cathelicidins (Gallo et al, 2002)—have been iden-
tified in mammalian tissue and have been shown to play an
essential role in host defense against invading microbes
(Nizet et al, 2001; Howell et al, 2004). Specifically, the anti-
bacterial activities of human b-defensin (HBD)-2 and LL-37
against S. aureus have been previously described (Ong et al,
2002). Additionally, we have demonstrated that inflamed skin
from psoriasis patients exhibits increased levels of AMP ex-
pression whereas patients with EAD do not (Ong et al, 2002;
Nomura et al, 2003). These studies were therefore conducted
to investigate the expression of HBD-2 and LL-37 in ecze-
matous skin lesions from IAD and EAD patients to determine
whether AMP were equally low in these two forms of AD and
investigate whether there might be a novel immune pathway
that explained the increased propensity to infection for IAD
and contribute to reduced AMP in EAD as well.
Results
AMP gene expression levels in psoriasis and AD
skin Skin explants were collected from the lesional skin
Abbreviations: ACD, allergic contact dermatitis; AD, atopic der-
matitis; AMP, anti-microbial peptide; EAD, extrinsic atopic derma-
titis; GAS, Group A Streptococcus; HBD, human beta defensin;
IAD, intrinsic atopic dermatitis; IFN, interferon; IL, interleukin;
PBMC, peripheral blood mononuclear cell; TNF, tumor necrosis
factor
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of normal subjects psoriasis, IAD, and EAD patients and
were evaluated for AMP gene expression using real-time
RT-PCR. In order to make comparisons between samples
and patient populations, AMP gene expression was nor-
malized to the endogenous control, GAPDH, for all samples.
As shown in Fig 1, HBD-2 expression was significantly
higher in skin lesions from psoriasis (mean: 6089  1868) as
compared with lesions from IAD (mean: 53.50  22.53;
p¼0.0003) or EAD (mean: 35.63  12.92; po0.0001).
Similarly, IAD (mean: 6.128  3.64) and EAD (mean:
4.16  1.73) skin lesions expressed significantly lower lev-
els of LL-37 expression than psoriasis (mean: 31.50  9.32;
p¼0.009 and 0.0002, respectively). Levels of HBD-2 and
LL-37 in normal skin were significantly lower (HBD-2:
p¼0.0007; LL-37: p¼0.0006) than psoriasis and were sim-
ilar to those previously observed (Ong et al, 2002). No sig-
nificant differences in AMP expression were observed
between IAD and EAD skin lesions.
In order to exclude disease severity as a means for de-
ficient AMP expression, we investigated the relationship
between SCORAD and AMP gene expression using regres-
sion analysis. There is no correlation between the severity
of disease and AMP expression (HBD-2: p¼0.25; LL-37:
p¼0.20) (data not shown).
Immunostaining for LL-37 in IAD and EAD Previously we
have shown that skin sections from psoriasis exhibit more
intense HBD-2 and LL-37 staining than EAD (Ong et al,
2002). To investigate AMP protein expression in IAD and
EAD, explants were stained with a polyclonal antibody di-
rected against LL-37. Allergic contact dermatitis (ACD) skin
was used as a control for immunostaining in these studies
because of the histological similarities of ACD with AD.
Figure 2A illustrates that skin sections from ACD patients
exhibited more intense staining for LL-37 than skin from
normal subjects, as well as IAD and EAD patients. The
composite data for LL-37 immunostaining in all samples are
shown in Fig 2B. The intensity of LL-37 staining in normal,
EAD, and IAD skin samples was significantly lower than
ACD (p¼ 0.008, 0.008, and 0.03, respectively). The granular
cell layer and stratum corneum of normal, IAD, and EAD
skin samples was almost devoid of LL-37 staining, as com-
pared with ACD.
AMP deﬁciency is acquired in AD To investigate whether
the reduced expression of AMP in AD skin is constitutive or
acquired, primary keratinocytes were isolated from the skin
of IAD, EAD, psoriasis, and normal subjects, and then
cultured for three passages to eliminate the in vivo effects
of inflammation. Differentiated primary keratinocytes were
stimulated with tumor necrosis factor (TNF)-a and interferon
(IFN)-g, to optimally induce HBD-2 (Ong et al, 2002) or
group A Streptococcus (GAS), which has previously been
shown to induce the expression LL-37 (Dorschner et al,
2001). In comparison with non-treated (NT) samples, HBD-2
was upregulated following stimulation with TNF-a and IFN-g
(Fig 3). There were no differences, however, between the
different skin types. Additionally, GAS induced greater LL-
37 expression in keratinocytes from normal, IAD, EAD, and
psoriasis patients; but no differences were observed be-
tween study groups (Fig 3).
Downregulatory role of IL-10 on AMP production Since
previous studies have demonstrated that IL-4 and IL-13 are
decreased in IAD, we sought another mechanism to explain
the deficiency of AMP in IAD. IL-10 is known to downreg-
ulate the pro-inflammatory response of mononuclear cells
and to be increased in AD (Ohmen et al, 1995). As depicted
in Fig 4, IL-10 was significantly elevated in IAD (mean:
1.34  0.45) and EAD (mean: 0.86  0.11) skin lesions when
compared with psoriasis (mean: 0.28  0.06; IAD: p¼ 0.02;
EAD: p¼ 0.003) and normal skin (mean: 0.30  0.06; IAD:
p¼0.02; EAD: p¼ 0.001). Using linear regression, we in-
vestigated whether there was a correlation between the
overexpression of IL-10 and reduced expression of AMP. In
IAD patients we observed a significant relationship between
the expression of IL-10 and HBD-2 (p¼0.017) and LL-37
(p¼0.043) (Fig 5). In contrast, there was no correlation be-
tween the expression of IL-10 and AMP in EAD patients.
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Figure 1
Decreased anti-microbial gene expression in extrinsic atopic der-
matitis (EAD) and intrinsic atopic dermatitis (IAD) patients. RNA
was isolated from the skin of normal subjects (’, n¼ 7), EAD (m, n¼9),
IAD (., n¼7), and psoriasis (E, n¼8), patients and the levels of hu-
man b-defensin (HBD)-2 (A) and LL-37 (B) evaluated by real-time PCR.
Significant differences between patient groups were determined by a
non-parametric Mann–Whitney test.
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Interestingly, however, the expression of both IL-10 and IL-
13 in lesional skin from EAD patients correlated with a de-
crease in both HBD-2 (p¼ 0.05) and LL-37 (p¼ 0.03).
The direct effect of IL-10 on AMP expression in keratin-
ocytes was assessed by stimulating the HaCaT human ker-
atinocyte cell line with TNF-a and IFN-g in the presence and
absence of IL-10 or IL-13. Stimulation with TNF-a and IFN-g
significantly increased HBD-2 (p¼ 0.0002) expression in
keratinocytes (data not shown). This induction was signif-
icantly inhibited by the addition of IL-13 (p¼ 0.001) but not
IL-10, suggesting that IL-10 does not act directly on ker-
atinocyte AMP expression.
To investigate the possibility that IL-10 acts indirectly on
AMP expression by reducing generation of pro-inflamma-
tory cytokines by mononuclear cells, peripheral blood
mononuclear cell (PBMC) were collected from normal sub-
jects and stimulated with anti-CD3 in the presence or ab-
sence of increasing concentrations of IL-10. Using real-time
PCR, we evaluated the levels of TNF-a and IFN-g gene ex-
pression in PBMC following stimulation. Additionally, the
Bio-Plex assay (Bio-Rad, Hercules, California) was used to
evaluate the levels of pro-inflammatory cytokines in the
supernatants of media or anti-CD3-stimulated PBMC. Anal-
ysis revealed that PBMC stimulated with anti-CD3 secreted
high levels of IL-1, IL-6, TNF-a, and IFN-g (data not shown),
i.e. cytokines that have been shown to induce AMP ex-
pression (Erdag and Morgan, 2002; Liu et al, 2002; Ong
et al, 2002; Nomura et al, 2003). TNF-a (po0.01) and IFN-g
(po0.01) mRNA levels were also elevated in anti-CD3-stim-
ulated PBMC (data not shown). The induction of both
cytokines was inhibited more than 10-fold by adding 5–50
ng per mL (TNF-a: po0.01; IFN-g: po0.05) of IL-10 to anti-
CD3-stimulated PBMC.
To test the effects of IL-10 on the downregulation of the
pro-inflammatory cytokines known to induce AMP in human
keratinocytes, supernatants from anti-CD3-stimulated
PBMC, cultured in the presence of increasing concentra-
tions of IL-10, were added to HaCaT cell cultures. Figure 6
illustrates that, in the absence of IL-10, supernatants from
anti-CD3-stimulated PBMC significantly induce the ex-
pression of HBD-2 (p¼0.022) and LL-37 (p¼ 0.002). Fifty
nanograms per milliliter of IL-10, however, reduced the
expression of HBD-2 by approximately 75%. Even greater
inhibition of AMP expression was observed in keratinocytes
exposed to a combination of exogenous IL-13 and supe-
rnatant from anti-CD3- and IL-10-stimulated PBMC. The
combination of the indirect effect of IL-10 on the pro-in-
flammatory cytokines and the direct effect of IL-13 on
keratinocytes significantly reduced AMP expression in
comparison with the effect of IL-10 (HBD-2: p¼0.067; LL-
37: po0.001) or IL-13 (HBD-2: p¼0.002; LL-37: p¼0.050)
alone. Direct stimulation of HaCaT cells with anti-CD3 did
not induce HBD-2 or LL-37 (data not shown).
Neutralization of IL-10 and IL-13 augments AMP expres-
sion in AD skin Previously we have demonstrated that
TNF-a and IFN-g are potent inducers of AMP expression in
keratinocytes (Ong et al, 2002) and that IL-10 downregu-
lates the production of these cytokines by normal PBMC. In
these studies, we additionally demonstrated that PBMC
from AD patients stimulated with anti-CD3 secrete higher
levels of IL-10 protein than PBMC from normals treated
under the same conditions (data not shown). Therefore,
PBMC were collected from AD patients to determine wheth-
er the downregulatory effect of IL-10 could be blocked by
neutralizing antibodies. PBMC were stimulated with anti-
CD3 in the presence or absence of anti-IL-10 and the levels
of TNF-a and IFN-g in the culture supernatants were deter-
mined by ELISA. Table I illustrates that levels of TNF-a and
IFN-g were less than 15.6 pg per mL in PBMC stimulated,
with media alone or media plus anti-IL-10. PBMC treated
with anti-CD3 plus anti-IL-10, however, released greater
levels of TNF-a (p¼0.05) and IFN-g (po0.05) protein into
the supernatant than anti-CD3-stimulated cells.
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Figure 2
Expression of LL-37 is increased in al-
lergic contact dermatitis but not extrin-
sic atopic dermatitis (EAD) or intrinsic
atopic dermatitis (IAD). (A) Paraffin-em-
bedded skin explants from EAD (n¼ 5), IAD
(n¼4), and allergic contact dermatitis
(n¼5) patients were cut into 5 mm sections
and stained for LL-37. Scale bars represent
25 mm. (B) The intensity of the immuno-
staining was visually scored on a scale from
0 to 5, with 0 indicating no staining and 5
the most intense staining. Significant differ-
ences between patient groups were deter-
mined by a non-parametric Mann–Whitney
test.
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To investigate whether low AMP in AD skin could be re-
versed, lesional skin from EAD patients was cultured with
neutralizing antibodies to IL-10 and IL-13 and assayed for
AMP expression. Addition of anti-IL-10 to skin explants re-
sulted in a significant increase in HBD-2 expression (mean:
1346.2  190.3; p¼0.007) and LL-37 expression (mean:
61.2  9.2; po0.001) (Fig 7). Interestingly, the addition of
anti-IL-13 to EAD skin explants augmented HBD-2 expres-
sion by 6-fold (mean: 3341.3  691.2; p¼0.004) and LL-37
expression by over 10-fold (mean: 113.5  12.3, po0.001).
Discussion
The epidermis is an immunologically rich layer of skin com-
prised largely of keratinocytes that differentiate into anu-
cleated cells to form the stratum corneum. The stratum
corneum is the skin’s first line of defense against invading
microbial pathogens. When this physical barrier is compro-
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Figure 3
Reduced anti-microbial peptide expression is an acquired defect
in primary keratinocytes from atopic dermatitis (AD) patients. The
levels of human b-defensin (HBD)-2 (A) and LL-37 (B) were evaluated
by real-time RT-PCR in differentiated keratinocytes obtained from nor-
mal subjects (E, n¼6), extrinsic AD (EAD) patients (m, n¼3), intrinsic
AD (IAD) patients (’, n¼3), and psoriatic patients (  , n¼6). HBD-2
was induced by 24 h stimulation with tumor necrosis factor-a (TNF-a)
plus interferon-g (IFN-g), and LL-37 with heat-inactivated group A
Staphylococcus extract (GAS). Samples treated with media alone are
indicated by non-treated (NT).
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Increased interleukin (IL)-10 gene expression in extrinsic atopic
dermatitis (EAD) and intrinsic atopic dermatitis (IAD) patients. RNA
was isolated from the skin of normal subjects (’, n¼7), EAD (m, n¼ 9),
IAD (., n¼ 7), and psoriasis (E, n¼8) patients and the levels of IL-10
evaluated by real-time PCR. Significant differences between patient
groups were determined by a non-parametric Mann–Whitney test.
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Figure5
Inverse relationship between interleukin (IL)-10 and anti-microbial
peptide (AMP) expression in intrinsic atopic dermatitis (IAD) pa-
tients. RNA was isolated from the skin of IAD (n¼ 7) patients. The
correlation between IL-10 and either human b-defensin (HBD)-2 (A) or
LL-37 (B) gene expression was evaluated using linear regression.
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mised, further invasion by the pathogen is prevented by the
innate immune response. AMP are an integral part of the
innate immune response as they have been shown to be
effective in killing bacterial (Ong et al, 2002) and viral (Howell
et al, 2004) pathogens.
This study demonstrates that the skin of both IAD and
EAD skin is deficient of AMP. Combined with a previous
study which demonstrated that the levels of LL-37 and
HBD-2 in psoriasis skin, but not AD skin, can kill S. aureus,
our observations may explain why both IAD and EAD exhibit
similar propensity to skin infections. But the primary mech-
anism(s) underlying the AMP deficiency may be different
between the two subsets of AD. Previous studies have
demonstrated that the Th2 cytokines, IL-4 and IL-13, inhibit
the expression of HBD-2 and HBD-3 in human keratin-
ocytes (Ong et al, 2002; Nomura et al, 2003). Additional
studies have demonstrated that patients with EAD
express higher levels of IL-13 in the lesional skin (Jeong
et al, 2003), skin T cells (Akdis et al, 1999), and PBMC (Kagi
et al, 1994) than IAD. Therefore, we investigated other
mechanisms to explain the decreased AMP expression in
patients with IAD.
Pro-inflammatory cytokines such as TNF-a, IL-6, IL-1,
and IFN-g have been shown to induce the expression of
AMP (Erdag and Morgan, 2002; Liu et al, 2002; Ong et al,
2002; Nomura et al, 2003). These cytokines are highly ex-
pressed in psoriasis skin (Grossman et al, 1989; Nomura
et al, 2003), whereas negligible levels of TNF-a and IFN-g
have been shown in AD skin (Nomura et al, 2003). Despite
higher levels of IFN-g in chronic as compared with acute
AD, skin explants from patients with chronic AD expressed
minimal levels of AMP. This is likely because of the fact that
pre-incubation of keratinocytes with IL-4/IL-13, as would be
the case in acute AD that has evolved into chronic AD, in-
hibits the induction of AMP expression by TNF-a and IFN-g
(Nomura et al, 2003). This does not, however, explain the
deficiency of AMP in IAD. Previous studies have demon-
strated that IL-10 is expressed by mononuclear cells in AD
and that the overexpression of IL-10 acts to inhibit or
downregulate the pro-inflammatory and Th1 immune re-
sponses (Lester et al, 1995; Ohmen et al, 1995; Asadullah
et al, 1998; Borish, 1998; Laouini et al, 2003).
Using real-time RT-PCR, we demonstrate that IL-10 is
elevated in both EAD and IAD lesional skin whereas neg-
ligible levels are expressed in psoriasis skin. Additionally,
we demonstrate an inverse relationship between the ex-
pression of IL-10 and AMP in lesional skin from IAD pa-
tients. In EAD skin, the expression of IL-10 did not correlate
with AMP expression; however, the expression of both IL-10
and IL-13 correlated with decreased AMP expression. This
further supports the immunoregulatory role of IL-10 in IAD
and added role of IL-13 plus IL-10 in EAD.
In this study and in previous studies (Ong et al, 2002;
Nomura et al, 2003), IL-13 has been shown to act directly on
the keratinocytes to downregulate the expression of the b-
defensin family. We found, however, that IL-10 does not act
on human keratinocytes to directly inhibit AMP expression.
This is likely due, in part, to the absence of IL-10R1 on
keratinocytes and the requirement for both IL-10 receptors
for signaling (Seifert et al, 2003). Previous studies have
demonstrated that IL-10 acts on mononuclear cells and
natural killer cells to inhibit the expression of pro-inflamma-
tory cytokines and IFN-g (de Waal Malefyt et al, 1991; Fi-
orentino et al, 1991; D’Andrea et al, 1993; Chernoff et al,
1995). Therefore, we explored the possibility that IL-10 in-
directly inhibits AMP expression by downregulating the ex-
pression of the pro-inflammatory cytokines in mononuclear
cells, thereby preventing the induction of the AMP. This
concept is supported by the following findings in our study.
Table I. Augmented TNF-a and IFN-c production in AD PBMC
treated with anti-IL-10
TNF-a (pg per mL) IFN-c (pg per mL)
Media o15.6 o15.6
Mediaþ anti-IL-10 o15.6 o15.6
Anti-CD3 150.0  19.2 574.2  171.5
Anti-CD3þanti-IL-10 209.0  18.5 1376.7  270.1
Significance of pp0.05 as compared with stimulation with anti-CD3
alone.
TNF-a, tumor necrosis factor-a; IFN-g, interferon-g; AD, atopic derma-
titis; PBMC, peripheral blood mononuclear cell; IL, interleukin.
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Figure 6
Anti-microbial expression in HaCaT keratinocytes is downregulat-
ed by interleukin (IL)-10 and IL-13. RNA was isolated from keratin-
ocytes stimulated with the supernatants from normal peripheral blood
mononuclear cell (n¼ 6) cultured with media or anti-CD3 (100 ng per
mL) in the presence or absence of IL-10 and/or IL-13 and the levels of
human b-defensin (HBD)-2 (A) and LL-37 (B) were evaluated by real-
time RT-PCR. Significant differences between exposure groups were
determined by a two-tailed t test.
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First, we have found that stimulation of normal PBMC with
anti-CD3 induces the expression of TNF-a, IL-6, IL-1, and
IFN-g. These cytokines have been previously reported to
increase AMP expression in keratinocytes (Erdag and Mor-
gan, 2002; Liu et al, 2002; Ong et al, 2002; Nomura et al,
2003). The addition of IL-10 to this system inhibited TNF-a
and IFN-g expression at both the mRNA and protein level.
Second, supernatant from normal PBMC stimulated with
anti-CD3, in the presence of IL-10, failed to induce the
expression of AMP in human keratinocytes. This is likely
to be because of the lack of the pro-inflammatory cytokines.
In contrast, supernatants from PBMC stimulated with
anti-CD3 in the absence of IL-10 induced significantly
greater expression of HBD-2 and LL-37 than media alone.
Our study additionally proposes the novel idea that IL-10
and IL-13 work through different mechanisms to syner-
gistically downregulate AMP expression in AD skin. By
stimulating PBMC in the presence of IL-10 and adding ex-
ogenous IL-13 to keratinocyte cultures, AMP expression
was inhibited to a greater degree than observed for each
cytokine alone.
The mechanism by which IL-10 inhibits cytokine pro-
duction in macrophages and natural killer cells is still un-
clear. IL-10 has, however, been shown to inhibit the
expression of B7.1 (CD80), B7.2 (CD86), and major histo-
compatibility complex II (MHC class II) expression in mon-
ocytes and Langerhan’s cells (Ding et al, 1993). B7 and
MHC class II are required for T cell activation and prolifer-
ation. By inhibiting the expression of these molecules in
monocytes, IL-10 is able to prevent T cell activation and the
subsequent release of pro-inflammatory cytokines (Ding
et al, 1993). Since IL-10 is highly expressed in both EAD and
IAD skin, this may explain the reduced levels of pro-inflam-
matory cytokines and negligible expression of the AMP.
Using antibodies against IL-10, we have directly dem-
onstrated that the downregulatory role of IL-10 on pro-in-
flammatory cytokines could be reversed in PBMC from AD
patients. Extending this observation, the addition of anti-IL-
10 to lesional skin explants from AD patients augmented
HBD-2 and LL-37 expression. The importance of this ob-
servation is further delineated by a previous study that
demonstrated reduced bacterial growth and lethality in
mice treated with anti-IL-10 prior to challenge with Strepto-
coccus pneumoniae (van der Sluijs et al, 2004). Based on
this study, we propose that neutralization of IL-10 in AD skin
may decrease the susceptibility of these individuals to re-
current bacterial and viral skin infections.
This study demonstrates that reduced expression of
AMP in AD is not constitutive but acquired as a result of
increased Th2 cytokine expression. Moreover, this study
demonstrates a novel mechanism by which AMP produc-
tion can be deficient in AD, i.e. because of increased IL-10
expression. We propose that IL-10 indirectly inhibits AMP
expression in keratinocytes by suppressing the production
of pro-inflammatory cytokines, known to induce AMP, by
mononuclear cells. This explains why, despite different clin-
ical characteristics, both EAD and IAD are deficient of AMP
and suffer from recurrent skin infections. Importantly, it
identifies a new therapeutic target for augmentation of host
defense, i.e. neutralization of IL-10 secretion in atopic skin
(Fig 7).
Materials and Methods
Subjects Study participants included six healthy controls (mean
age: 44.2 y), seven IAD patients (mean age: 29.1 y; SCORAD:
22.2  5.6; serum IgE: 34–146 kU per liter), 14 EAD patients (mean
age: 38.7 y; SCORAD: 45.0  11.5; serum IgE: 288–5000 kU per
liter), eight psoriasis patients (mean age: 39.7 y; 15%–40% skin
involvement), and five ACD patients (mean age: 60.6 y). Sera from
AD patients were tested against house dust mite, Aspergillus,
Candida albicans, birch pollen, timothy grass pollen, ragweed,
apple, milk, egg, peanut, hazelnut, Staphylococcus enterotoxin A,
and Staphylococcus enterotoxin B for specific IgE with the Immu-
lite 2000 system (DPC Biermann, Bad Nauheim, Germany). The
skin prick test was conducted with the following allergens: house
dust mite, grass, birch pollen, Aspergillus, C. albicans, milk, egg,
soy, and peanut. Patients with IAD had no allergen-specific IgE and
were skin prick test negative to inhalant and food allergens. In
contrast, patients with EAD had allergen-specific IgE and were skin
prick test positive to inhalant and food allergens.
None of the patients had received oral corticosteroids within 1
mo of skin explant, and topical corticosteroids were not allowed for
a period of at least 1 wk prior to enrollment. These studies were
conducted according to the Declaration of the Helsinki Guidelines
and were approved by the institutional review board at National
Jewish Medical and Research Center in Denver, the University of
Bonn Medical Center in Germany, and the Istituto Dermopatico
dell’Immacolata in Italy. All subjects gave written informed consent
prior to enrollment.
PBMC culture PBMC were isolated from heparinized blood using
Ficoll–Hypaque (Pharmacia Biotech, Piscataway, New Jersey)
centrifugation and suspended in RPMI 1640 (Bio-Whittaker, Walk-
ersville, Maryland) as previously described (Hauk et al, 2000).
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Figure7
Neutralization of interleukin (IL)-10 and IL-13 in atopic dermatitis
(AD) skin augments anti-microbial peptide expression. Lesional
skin from extrinsic AD patients (n¼5) was cultured in the presence of
anti-IL-10 (1 mg per mL) or anti-IL-13 (1 mg per mL) for 24 h and the
levels of human b-defensin (HBD)-2 (A) and LL-37 (B) evaluated by real-
time RT-PCR. Significant differences between exposure groups were
determined by a two-tailed t test.
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PBMC were isolated from subjects and seeded at 1  106 cells per
mL in 25 cm2 flasks in the presence or absence of 100 ng per mL of
anti-CD3. To investigate the effects of IL-10 on anti-CD3-stimulat-
ed normal PBMC, up to 50 ng per mL of IL-10 (R&D Systems,
Minneapolis, Minnesota) was added to corresponding flasks and
cultured for 24 h. Conversely, 1 mg per mL of anti-IL-10 (R&D Sys-
tems) was added to anti-CD3-stimulated PBMC from AD patients
and cultured for 24 h. Following the incubation period, the supe-
rnatant was collected from stimulated PBMC and either stored at
801C until further analysis or added to cultured HaCaT keratin-
ocyte cells (2  105 cells per well) in 24-well plates. RNA was
isolated from PBMC according to the manufacturer’s guidelines
(Qiagen, Valencia, California).
Cytokine protein analysis Cytokine quantification was per-
formed on supernatants from stimulated PBMC. The Bio-Plex
human cytokine 17-plex panel was purchased from Bio-Rad
Laboratories and analyzed using the Bio-Plex array reader (Bio-
Rad Laboratories) according to the manufacturer’s guidelines.
TNF-a and IFN-g were further evaluated in supernatants using
Quantikine ELISA kits according to the manufacturer’s guidelines
(R&D Systems). Data were calculated as mean picograms (pg) per
mL  standard error.
Keratinocyte and skin explant cultures Primary keratinocytes
were isolated from six patients with moderate-to-severe chronic
IAD or EAD (age range: 19–45 y), six patients with moderate-
to-severe chronic plaque psoriasis (age range: 32–49 y), and six
healthy control subjects (age range: 25–50 y). In these experi-
ments, epidermal sheets were procured from the roof of suction
blisters raised on normal-appearing skin of the forearms of patients
with IAD or EAD, patients with psoriasis or healthy subjects, and
primary keratinocyte cultures were obtained as described (Pastore
et al, 1997). Keratinocytes were routinely grown in serum-free
keratinocyte growth medium (Clonetics, San Diego, California),
prepared from the essential nutrient solution keratinocyte basal
medium supplemented with 10 ng per mL epidermal growth fac-
tor (Clonetics), 0.4 mg per mL hydrocortisone (Clonetics), bovine
pituitary extract (Clonetics), and antibiotics. To study AMP gene
expression, keratinocyte cultures were differentiated in the pres-
ence of 1.3 mM CaCl2 for 3 d and then stimulated for 24 h with a
combination of 20 ng per mL TNF-a (R&D Systems, Abingdon, UK)
and 200 U per mL IFN-g (R&D Systems), or with 1 per 10 dilution in
culture medium of heat-inactivated GAS (strain NZ131) extract.
The cells were then washed once and homogenized in buffer RLT
(Qiagen). Total RNA was isolated according to the manufacturer’s
protocol in the presence of DNase I (Qiagen) for real-time RT-PCR.
The HaCaT human keratinocyte cell line was grown in
Dulbecco’s modified Eagle’s medium (Cellgro, Herndon, Virginia),
supplemented with 10% fetal calf serum (Gemini Bio Products,
Calabasas, California) and 1% of the following: penicillin/strepto-
mycin, L-glutamine, minimal essential medium (MEM) with non-
essential amino acids (GIBCO, Grand Island, New York), MEM vi-
tamins solution (GIBCO) until confluent. Once confluent, cells were
split and seeded in 24-well plates at 2  105 cells per well and
cultured for 24 h to allow adherence. To examine the direct effect of
IL-10 on AMP production, HaCaT cells were stimulated with 20 ng
per mL TNF-a (R&D Systems) and 200 U per mL IFN-g (R&D Sys-
tems) in the presence and absence of either 50 ng per mL IL-10
and/or 50 ng per mL IL-13 (R&D Systems). Following a 24 h in-
cubation, media were removed and RNA isolated from keratin-
ocytes according to the manufacturer’s guidelines (Qiagen). The
indirect effect of IL-10 on AMP expression was assessed by add-
ing culture supernatants from PBMC experiments to HaCaT cells.
In some cases, IL-13 was added to the cultures in order to de-
termine the combinatory effect of IL-13 on the keratinocytes and
IL-10 on the pro-inflammatory cytokines and AMP expression.
Cells were cultured for 24 h and RNA isolated from HaCaT cells
according to the manufacturer’s guidelines (Qiagen) for real-time
RT-PCR.
Skin explants were cultured under various conditions in com-
plete RPMI 1640 (Bio-Whittaker). To investigate whether the base-
line levels of AMP expression were similar between normal and AD
patients; punch biopsies were collected from non-lesional skin of
four AD patients as well as four normal subjects and added to 96-
well tissue culture plates. Culture supernatants from either media
or anti-CD3-stimulated PBMC were added to skin explants and
allowed to culture for 24 h. Following exposure, RNA was isolated
from skin explants for real-time RT-PCR. In another experiment,
lesional skin from five EAD patients was cultured ex vivo in com-
plete RPMI 1640 (Bio-Whittaker). Anti-IL-10 (R&D Systems) or anti-
IL-13 (R&D Systems) were added to skin explants for 24 h to
investigate the effect of Th2 cytokine neutralization on AMP ex-
pression. Following exposure, RNA was isolated from skin explants
for real-time RT-PCR.
RNA preparation and analysis Total RNA was isolated from skin
explants by chloroform:phenol extraction and isopropanol precip-
itation according to the manufacturer’s guidelines (Sigma Chemical
Co., St Louis, Missouri). RNeasy Mini Kits (Qiagen) were used ac-
cording to the manufacturer’s protocol to isolate RNA from cell
cultures and to further purify RNA from skin explants. One micro-
gram of RNA was reverse transcribed in a 20 mL reaction contain-
ing Random Primers (Invitrogen, Carlsbad, California), RNase
Inhibitor (Invitrogen), and Superscript II enzyme (Invitrogen). Real-
time PCR was performed and analyzed by the dual-labeled fluor-
igenic probe method using an ABI Prism 7000 sequence detector
(Applied Biosystems, Foster City, California). Primers and probes
for human IL-10, TNF-a, IFN-g, and GAPDH were purchased from
Applied Biosystems. HBD-2 and LL-37 primer and probes were
prepared as previously described (Ong et al, 2003). The TaqMan
probes were purchased from Applied Biosystems and were 50
labeled with 6-carboxyfluorescein and 30 labeled with 6-carboxy-
tetramethylrhodamine. Amplification reactions were performed in
MicroAmp optical tubes (Applied Biosystems) in a 25 mL volume
containing 2  TaqMan Master Mix (Applied Biosystems), 900 nM
forward primer, 900 nM reverse primer, 200 nM probe, and the
template RNA. Thermal cycling conditions were: 501C for 2 min,
951C for 10 min for one cycle. Subsequently, 40 cycles of ampli-
fication were performed at 941C for 15 s and 601C for 1 min. Rel-
ative expression levels were calculated by the relative standard
curve method as outlined in the manufacturer’s technical bulletin. A
standard curve was generated using the fluorescent data from 10-
fold serial dilutions of total RNA of the highest expression sample.
To allow for comparisons between samples and groups, quantities
of all targets in test samples were normalized to the corresponding
GAPDH levels in the skin explants, cultured keratinocytes, and
PBMC, and expressed as Target Gene normalized to GAPDH.
Immunohistochemistry for LL-37 Skin explants were submerged
in 10% buffered formalin for immunostaining. Paraffin-embedded
tissues were cut at 5 mm and placed on frosted microscope slides.
Using toluene and a series of ethanol washes, slides were de-
paraffinized and then re-hydrated. Tissue sections were then im-
mersed in antigen retrieval solution (0.01 M citric acid, 0.05 M
NaOH, pH 6.0) and microwaved for 4 min. Endogenous peroxidase
was blocked by incubating slides for 30 min in a 0.3% H2O2 so-
lution. Skin sections were then blocked with 2% goat serum and
3% bovine serum albumin in PBS for 30 min and then stained with
rabbit anti-LL-37 (5 mg per mL) as previously described (Dorschner
et al, 2001). Sections were washed in PBS, stained with goat anti-
rabbit horseradish peroxidase (Vectastain Elite ABC Rabbit kit,
Vector Laboratories, Burlingame, California), and detected with di-
aminobenzidine substrate (Sigma Chemical Co.) according to the
manufacturer’s instructions. The skin sections were counterstained
with hematoxylin. Primary antibody specificity was confirmed in
separate experiments by adsorption of anti-LL-37 antibody with
excess amounts of the synthetic peptide. Specificity of the goat
anti-rabbit antibody and immunostaining reagents was confirmed
by routine use of the rabbit non-immune sera.
744 HOWELL ET AL THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
All slides were coded before the samples were evaluated so
that the identity of the patients would be blinded to the observer.
Images were collected at  40 magnification and the intensity
of the immunostaining was scored on a scale from 0 to 5, with
0 indicating no staining and 5 the most intense staining.
Statistical analyses Statistical analysis was conducted using
Graph Pad Prism, version 3.01 (San Diego, California) and SAS
(Research Triangle Park, North Carolina). Statistical differences in
gene expression or protein staining between groups were deter-
mined using a non-parametric Mann–Whitney test, with significant
differences conferred when pp0.05. In cases where multiple ex-
posure groups were compared with a control, data were analyzed
by a one-way ANOVA and significant differences between expo-
sure groups were determined by a Tukey–Kramer test. Regression
analysis was performed using PROC GLM in SAS.
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